M. C. Muller

1.0k total citations
7 papers, 350 citations indexed

About

M. C. Muller is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, M. C. Muller has authored 7 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 5 papers in Genetics and 4 papers in Pathology and Forensic Medicine. Recurrent topics in M. C. Muller's work include Chronic Myeloid Leukemia Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Lymphoma Diagnosis and Treatment (4 papers). M. C. Muller is often cited by papers focused on Chronic Myeloid Leukemia Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Lymphoma Diagnosis and Treatment (4 papers). M. C. Muller collaborates with scholars based in Germany, France and Czechia. M. C. Muller's co-authors include Andreas Hochhaus, Tanja Lahaye, Rüdiger Hehlmann, Christian Kühn, Sebastian Kreil, A Weißer, Kirsten Merx, Harald Gschaidmeier, Claudia Schoch and Peter Paschka and has published in prestigious journals such as Leukemia, Haematologica and Current Cancer Drug Targets.

In The Last Decade

M. C. Muller

7 papers receiving 336 citations

Peers

Countries citing papers authored by M. C. Muller

Since Specialization

Citations

This map shows the geographic impact of M. C. Muller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. C. Muller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. C. Muller more than expected).

Fields of papers citing papers by M. C. Muller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. C. Muller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. C. Muller. The network helps show where M. C. Muller may publish in the future.

Co-authorship network of co-authors of M. C. Muller

This figure shows the co-authorship network connecting the top 25 collaborators of M. C. Muller. A scholar is included among the top collaborators of M. C. Muller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. C. Muller. M. C. Muller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	STOPPING TYROSINE KINASE INHIBITORS IN A VERY LARGE COHORT OF EUROPEAN CHRONIC MYELOID LEUKEMIA PATIENTS: RESULTS OF THE EURO-SKI TRIAL 2016 ·Data Archiving and Networked Services (DANS) ·Johan Richter, F.-X. Mahon, Joëlle Guilhot, Henrik Hjorth‐Hansen, António Almeida, J. Janssen, Jiřı́ Mayer, Kimmo Porkka, (unknown), Ulla Olsson‐Strömberg, (unknown), (unknown), Hans Ehrencrona, Veli Kairisto, Kateřina Machová Poláková, M. C. Muller, Satu Mustjoki, Andreas Hochhaus, Markus Pfirrmann, Susanne Saußele	15
2	Current Treatment Concepts of CML 2010 ·Current Cancer Drug Targets ·Alfred Leitner, Andreas Hochhaus, M. C. Muller	18
3	ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia 2008 ·Haematologica ·Thomas Ernst, (unknown), Philipp Erben, Benjamin Hanfstein, Armin Leitner, R. Hehlmann, Andreas Hochhaus, M. C. Muller	41
4	Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure 2007 ·Haematologica ·Alice Fabarius, Claudia Haferlach, M. C. Muller, Philipp Erben, Tanja Lahaye, Michael Giehl, Oliver Frank, Wolfgang Seifarth, R. Hehlmann, Andreas Hochhaus	29
5	Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization 2002 ·Leukemia ·M. C. Muller, Kirsten Merx, (unknown), Sebastian Kreil, Tanja Lahaye, Rüdiger Hehlmann, Andreas Hochhaus	49
6	Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α 2002 ·Leukemia ·Kirsten Merx, M. C. Muller, Sebastian Kreil, Tanja Lahaye, Peter Paschka, Claudia Schoch, A Weißer, Christian Kühn, Ursula Berger, Harald Gschaidmeier, Rüdiger Hehlmann, Andreas Hochhaus	124
7	Detection and quantification of residual disease in chronic myelogenous leukemia 2000 ·Leukemia ·Andreas Hochhaus, A Weißer, Paul La Rosée, Michael Emig, M. C. Muller, Susanne Saußele, Andreas Reiter, Christian Kühn, Ute Berger, R. Hehlmann, Nicholas C.P. Cross	74

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact